Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis
Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational fixed-dose combination with Keytruda (pembrolizumab) in the KeyVibe program.
Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...
Merck is discontinuing the phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung ...
US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...
Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...
The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback